GLAUKOS Corp
GKOSNYSE
$156.83
↑ +0.9%Jul 17 close · end-of-day
Price
1Y↑ +59.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$9.1B
Enterprise Value
$9.0B
P/E
—
P/S
16.5
P/B
13.6
EV/EBITDA
—
PEG
—
FCF Yield
-0.2%
Dividend Yield
—
Revenue (TTM)
$551.3M
Net Income (TTM)
-$189.3M
Free Cash Flow (TTM)
-$18.5M
Gross Margin
57.6%
Operating Margin
-36.0%
Net Margin
-34.3%
ROE
-28.2%
ROIC
-27.7%
Debt / Equity
—
Net Cash
$104.2M
Return 1Y
+58.4%
Company profile
Glaukos Corporation focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally.
- CEO
- Thomas W. Burns
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 780
- Headquarters
- California
- Website
- glaukos.com
Management & directors
- Thurman Alex R.SVP & CHIEF FINANCIAL OFFICER
- Navratil TomasCHIEF DEVELOPMENT OFFICER
- Burns Thomas WilliamCHAIRMAN & CEO
- Gilliam Joseph EPRESIDENT & COO
Roles derived from SEC Form 4 filings.
Earnings
GKOS Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$150.6M↑ +41.2%
Diluted EPS-$0.34↑ +6.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $225.0M | $294.0M | $282.9M | $314.7M | $383.5M | $507.4M |
| Gross profit | $133.2M | $227.4M | $213.9M | $239.1M | $289.5M | $282.8M |
| Operating income | -$123.6M | -$32.9M | -$82.3M | -$128.7M | -$122.4M | -$199.6M |
| Net income | -$120.3M | -$49.6M | -$99.2M | -$134.7M | -$146.4M | -$187.7M |
| Diluted EPS | -$2.70 | -$1.07 | -$2.09 | -$2.78 | -$2.77 | -$3.28 |
| Operating cash flow | -$23.0M | $24.7M | -$33.1M | -$57.8M | -$61.3M | -$14.8M |
| Free cash flow | -$29.9M | -$23.1M | -$63.3M | -$78.0M | -$67.6M | -$22.5M |
| Gross margin | 59.2% | 77.3% | 75.6% | 76.0% | 75.5% | 55.7% |
| Operating margin | -54.9% | -11.2% | -29.1% | -40.9% | -31.9% | -39.3% |
| Net margin | -53.5% | -16.9% | -35.1% | -42.8% | -38.2% | -37.0% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $95.7M | $96.7M | $105.5M | $106.7M | $124.1M | $133.5M | $143.1M | $150.6M |
| Gross profit | $73.1M | $74.1M | $76.9M | $82.3M | $97.2M | $104.7M | -$1.5M | $117.2M |
| Operating income | -$30.0M | -$24.7M | -$28.7M | -$20.7M | -$22.7M | -$16.4M | -$139.9M | -$19.9M |
| Net income | -$50.5M | -$21.4M | -$33.6M | -$18.1M | -$19.7M | -$16.2M | -$133.7M | -$19.8M |
| Diluted EPS | -$1.00 | -$0.39 | -$0.56 | -$0.32 | -$0.34 | -$0.28 | -$2.34 | -$0.34 |
| Operating cash flow | -$18.4M | -$9.6M | $507,000.00 | -$18.5M | $7.0M | -$10.1M | $6.8M | -$12.5M |
| Free cash flow | -$20.5M | -$11.0M | -$1.2M | -$20.5M | $5.8M | -$11.7M | $3.9M | -$16.5M |
| Gross margin | 76.4% | 76.6% | 72.9% | 77.2% | 78.3% | 78.4% | -1.1% | 77.9% |
| Operating margin | -31.3% | -25.5% | -27.2% | -19.4% | -18.3% | -12.3% | -97.7% | -13.2% |
| Net margin | -52.8% | -22.1% | -31.8% | -17.0% | -15.8% | -12.2% | -93.4% | -13.1% |
Company news
Jul 14, 2026
Jul 8, 2026
- 11d agoAbbott Labs vs. Glaukos: Which Healthcare Stock Is a Better Buy in 2026?fool.com
- 12d agoGKOS Stock Up More Than 45% Since May-End: What's Driving the Rally?finance.yahoo.com
- 12d agoThis Glaucoma Therapy Company Is Keeping An Eye On Profitsfinance.yahoo.com
- 12d agoGlaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29finance.yahoo.com
Jul 6, 2026
Jun 29, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-09 | Thurman Alex R.· SVP & CHIEF FINANCIAL OFFICER | Sale | 10,000 | $155.00 | $1.6M | filing |
| 2026-07-09 | Thurman Alex R.· SVP & CHIEF FINANCIAL OFFICER | Option exercise | 10,000 | $38.68 | $386,800.00 | filing |
| 2026-07-06 | Thurman Alex R.· SVP & CHIEF FINANCIAL OFFICER | Sale | 10,000 | $150.00 | $1.5M | filing |
| 2026-07-06 | Thurman Alex R.· SVP & CHIEF FINANCIAL OFFICER | Option exercise | 10,000 | $38.68 | $386,800.00 | filing |
| 2026-07-01 | Navratil Tomas· CHIEF DEVELOPMENT OFFICER | Sale | 716 | $139.06 | $99,566.96 | filing |
| 2026-06-25 | Burns Thomas William· CHAIRMAN & CEO | Tax withholding | 4,059 | $142.57 | $578,691.63 | filing |
| 2026-06-25 | Gilliam Joseph E· PRESIDENT & COO | Tax withholding | 1,056 | $142.57 | $150,553.92 | filing |
| 2026-06-25 | Navratil Tomas· CHIEF DEVELOPMENT OFFICER | Tax withholding | 483 | $142.57 | $68,861.31 | filing |
| 2026-06-16 | Navratil Tomas· CHIEF DEVELOPMENT OFFICER | Sale | 1,537 | $130.68 | $200,855.16 | filing |
| 2026-05-28 | Kliman Gilbert H | Award | 1,878 | $0.00 | $0.00 | filing |
| 2026-05-28 | WEN LEANA | Award | 1,878 | $0.00 | $0.00 | filing |
| 2026-05-28 | WEISNER AIMEE S | Award | 1,878 | $0.00 | $0.00 | filing |
| 2026-05-28 | Torres Denice | Award | 1,878 | $0.00 | $0.00 | filing |
| 2026-05-28 | Foley Mark J | Award | 1,878 | $0.00 | $0.00 | filing |
| 2026-05-28 | Hoffmeister David F | Award | 1,878 | $0.00 | $0.00 | filing |
| 2026-05-28 | Stapley Marc | Award | 1,878 | $0.00 | $0.00 | filing |
| 2026-05-26 | Hoffmeister David F | Option exercise | 15,000 | $24.69 | $370,350.00 | filing |
| 2026-05-14 | Kliman Gilbert H | Sale | 5,000 | $140.76 | $703,800.00 | filing |
| 2026-05-14 | Kliman Gilbert H | Option exercise | 5,000 | $24.69 | $123,450.00 | filing |
| 2026-05-11 | Kliman Gilbert H | Sale | 5,000 | $135.00 | $675,000.00 | filing |
| 2026-05-11 | Kliman Gilbert H | Option exercise | 5,000 | $24.69 | $123,450.00 | filing |
| 2026-05-01 | Gilliam Joseph E· PRESIDENT & COO | Sale | 19,573 | $143.54 | $2.8M | filing |
| 2026-05-01 | WEN LEANA | Sale | 1,700 | $143.35 | $243,695.00 | filing |
| 2026-04-30 | Thurman Alex R.· SVP & CHIEF FINANCIAL OFFICER | Sale | 10,000 | $140.00 | $1.4M | filing |
| 2026-04-30 | Thurman Alex R.· SVP & CHIEF FINANCIAL OFFICER | Option exercise | 10,000 | $38.68 | $386,800.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.